Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma

What's the purpose of this trial?

Compassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma

This trial is currently open and accepting patients.


You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

INCLUSION CRITERIA:

  • Written informed consent
  • Diagnosis of RRMM and/or plasma cell dyscrasias and:
    • Has failed 4 prior therapies
    • Is refractory to and IMID and to a proteasome inhibitor and to an anti CD-38 antibody (alone or in combinations if available)
  • Disease Progression on last therapy
  • Able to obtain ophthalmic examinations at baseline, before the subsequent 3 treatment cycles and as clinically indicated
  • Contraception requirements
    • Female Participants: A female patient is eligible to participate if one of the following conditions applies:
      • The patient Is not a woman of childbearing potential (WOCBP)OR
      • The patient Is a WOCBP and using an effective contraceptive method during treatment with belantamab mafodotin and for 4 months after the last dose. The patient must also have a negative highly sensitive serum pregnancy test within 72 hours of dosing on C1D1. Please discuss with GSK physician if the patient is pregnant, breast-feeding or planning to have a baby.
    • Male participants with female partners of child-bearing potential are eligible to participate if they agree to use effective contraception during treatment with belantamab mafodotin until 6 months after the last dose

EXCLUSION CRITERIA:

  • Evidence of Active Bleeding
  • Currently Active GVHD
  • Known Hypersensitivity to the active substance or to any of the excipients
  • Previous progression on belantamab mafodotin

US Expanded Access (group) Protocol:

INCLUSION CRITERIA:

For patients currently receiving BLENREP through the REMS program

  • Patients currently enrolled in the BLENREP REMS program who have received at least 1 dose of BLENREP
  • Written informed consent can be obtained from the patient or legally authorized representative as per local regulations

For new patients

  • New patients diagnosed with RRMM who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
  • No other treatment options available
  • Written informed consent can be obtained from the patient or legally authorized representative as per local regulations

EXCLUSION CRITERIA:

For patients currently receiving BLENREP through the REMS program

  • Previously progressed on treatment with belantamab mafodotin.
  • Patient is pregnant or breastfeeding

For new patients

  • Previously progressed on treatment with belantamab mafodotin.
  • Patient is pregnant or breastfeeding

Additional Trial Information

Expanded Access

View More

Trial Resources

GSK Compassionate Use (Expanded Access) Request Portal

February 06, 2023

GSK recognises that there may be circumstances when it is appropriate for Healthcare Professionals to give their patients Investigational medicines to treat life threatening or seriously debilitating diseases/conditions where no satisfactory alternatives exist.

Learn more

Trial Links

Read the latest news and updates on this trial.

FDA Panel Supports Belantamab Mafodotin for Relapsed/Refractory Myeloma

July 14, 2020

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to 0 in favor of approving belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have previously received at least 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and a CD38-directed antibody.

Read more
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message